vasopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
vasoconstrictors, vasopressin derivatives 2810 113-79-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vasopressin
  • 8-L-arginine vasopressin
  • synthetic vasopressin
  • 8-L-Arginine-vasopressin
  • argipressin
  • vasopressin tannate
  • vasopressin injection
  • antidiuretic hormone
  • pitressin tannate
  • Molecular weight: 1084.24
  • Formula: C46H65N15O12S2
  • CLOGP: -2.31
  • LIPINSKI: 3
  • HAC: 27
  • HDO: 15
  • TPSA: 461.43
  • ALOGS: -3.93
  • ROTB: 19

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
40 U P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI

Approvals:

DateAgencyCompanyOrphan
None FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiogenic shock 168.61 37.67 57 3799 16268 56271943
Hypotension 150.03 37.67 129 3727 250379 56037832
Shock 134.61 37.67 52 3804 21676 56266535
Cardiac arrest 132.41 37.67 79 3777 86235 56201976
Drug ineffective 129.38 37.67 226 3630 918763 55369448
Septic shock 110.00 37.67 62 3794 60773 56227438
Intentional overdose 103.48 37.67 62 3794 68055 56220156
Metabolic acidosis 94.81 37.67 49 3807 40405 56247806
Multiple organ dysfunction syndrome 93.25 37.67 53 3803 52717 56235494
Vasoplegia syndrome 88.05 37.67 20 3836 1305 56286906
Pulseless electrical activity 86.37 37.67 28 3828 6996 56281215
Acute kidney injury 78.21 37.67 89 3767 240674 56047537
Toxicity to various agents 76.32 37.67 85 3771 224479 56063732
Lactic acidosis 69.21 37.67 38 3818 35308 56252903
Circulatory collapse 69.12 37.67 32 3824 20771 56267440
Local anaesthetic systemic toxicity 59.29 37.67 13 3843 721 56287490
Peripheral ischaemia 55.71 37.67 18 3838 4445 56283766
Disseminated intravascular coagulation 48.69 37.67 24 3832 17861 56270350
Diabetes insipidus 48.20 37.67 14 3842 2423 56285788
Hypothermia 47.15 37.67 21 3835 12449 56275762
Respiratory failure 44.85 37.67 43 3813 95019 56193192
Pulmonary oedema 44.63 37.67 33 3823 51110 56237101
Acute respiratory distress syndrome 38.61 37.67 22 3834 21904 56266307
Ventricular tachycardia 38.19 37.67 20 3836 16881 56271330
Haemodynamic instability 37.94 37.67 16 3840 8313 56279898

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiogenic shock 425.16 39.26 160 5915 22248 31669021
Appendicolith 412.73 39.26 113 5962 5618 31685651
Multiple organ dysfunction syndrome 364.32 39.26 201 5874 68002 31623267
Appendicitis 335.45 39.26 113 5962 11352 31679917
Stress 305.48 39.26 130 5945 24811 31666458
Ascites 215.98 39.26 120 5955 40893 31650376
Drug ineffective 198.39 39.26 304 5771 395269 31296000
Abdominal distension 187.35 39.26 118 5957 50566 31640703
Sepsis 175.22 39.26 178 5897 151751 31539518
Ventricular fibrillation 171.91 39.26 80 5995 18768 31672501
Hyponatraemia 158.16 39.26 123 5952 73676 31617593
General physical health deterioration 128.83 39.26 132 5943 113303 31577966
Diabetes insipidus 128.19 39.26 38 6037 2502 31688767
Vasoplegia syndrome 96.88 39.26 28 6047 1685 31689584
Abdominal pain 90.89 39.26 125 5950 145827 31545442
Constipation 89.20 39.26 114 5961 123877 31567392
Blood phosphorus increased 88.34 39.26 33 6042 4449 31686820
Shock 71.86 39.26 48 6027 22597 31668672
Hypotension 69.38 39.26 133 5942 204485 31486784
Off label use 58.79 39.26 172 5903 347102 31344167
Vomiting 54.27 39.26 127 5948 223846 31467423
Renal injury 52.70 39.26 30 6045 10635 31680634
Lactic acidosis 49.03 39.26 44 6031 31893 31659376
Cardiac arrest 48.96 39.26 72 6003 88990 31602279
Diarrhoea 44.98 39.26 7 6068 352402 31338867
Fatigue 44.30 39.26 6 6069 335200 31356069
Serotonin syndrome 43.80 39.26 33 6042 18740 31672529
Pulse absent 43.37 39.26 21 6054 5356 31685913
Septic shock 41.52 39.26 57 6018 66101 31625168
Metabolic acidosis 41.05 39.26 44 6031 39533 31651736
Respiratory failure 40.62 39.26 71 6004 101378 31589891
Compartment syndrome 39.61 39.26 16 6059 2655 31688614

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiogenic shock 581.64 29.03 211 9756 36096 70882381
Appendicolith 443.14 29.03 112 9855 5568 70912909
Multiple organ dysfunction syndrome 436.50 29.03 239 9728 108276 70810201
Appendicitis 323.67 29.03 112 9855 16621 70901856
Drug ineffective 304.72 29.03 500 9467 939252 69979225
Stress 222.33 29.03 131 9836 67835 70850642
Ascites 207.40 29.03 125 9842 67422 70851055
Sepsis 206.05 29.03 210 9757 244335 70674142
Ventricular fibrillation 195.62 29.03 89 9878 27022 70891455
Vasoplegia syndrome 191.56 29.03 51 9916 3105 70915372
Shock 181.51 29.03 96 9871 40329 70878148
Hypotension 176.10 29.03 248 9719 404133 70514344
Diabetes insipidus 171.78 29.03 51 9916 4620 70913857
Abdominal distension 145.05 29.03 119 9848 104550 70813927
Cardiac arrest 143.04 29.03 142 9825 159692 70758785
Hyponatraemia 128.25 29.03 134 9833 159953 70758524
Metabolic acidosis 123.31 29.03 94 9873 74252 70844225
Septic shock 114.04 29.03 107 9860 112151 70806326
Lactic acidosis 107.34 29.03 82 9885 64942 70853535
Intentional overdose 92.68 29.03 90 9877 98345 70820132
General physical health deterioration 92.47 29.03 138 9829 235893 70682584
Acute kidney injury 86.13 29.03 199 9768 474425 70444052
Blood phosphorus increased 85.03 29.03 33 9934 6737 70911740
Pulseless electrical activity 81.67 29.03 39 9928 13176 70905301
Respiratory failure 79.82 29.03 108 9859 168627 70749850
Fatigue 77.17 29.03 12 9955 824307 70094170
Toxicity to various agents 65.67 29.03 157 9810 382015 70536462
Haemodynamic instability 64.09 29.03 35 9932 15623 70902854
Peripheral ischaemia 60.76 29.03 28 9939 8730 70909747
Acute respiratory distress syndrome 59.35 29.03 48 9919 41206 70877271
Headache 57.65 29.03 7 9960 580398 70338079
Overdose 57.64 29.03 93 9874 169652 70748825
Off label use 56.85 29.03 230 9737 742830 70175647
Renal injury 55.10 29.03 32 9935 16062 70902415
Abdominal pain 54.94 29.03 137 9830 341990 70576487
Constipation 54.87 29.03 114 9853 252324 70666153
Circulatory collapse 54.71 29.03 43 9924 35431 70883046
Serotonin syndrome 54.33 29.03 46 9921 42068 70876409
Arthralgia 52.71 29.03 5 9962 503385 70415092
Dizziness 50.25 29.03 4 9963 464137 70454340
Pulse absent 50.04 29.03 25 9942 9305 70909172
Drug ineffective for unapproved indication 49.52 29.03 42 9925 38496 70879981
Local anaesthetic systemic toxicity 47.87 29.03 13 9954 852 70917625
Hyperdynamic left ventricle 47.87 29.03 11 9956 362 70918115
Distributive shock 43.31 29.03 15 9952 2222 70916255
Compartment syndrome 42.98 29.03 18 9949 4468 70914009
Rash 42.23 29.03 10 9957 510552 70407925
Bradycardia 40.54 29.03 67 9900 124548 70793929
Electrocardiogram QRS complex prolonged 40.35 29.03 22 9945 9784 70908693
Diarrhoea 40.11 29.03 31 9936 783310 70135167
Heparin-induced thrombocytopenia 39.21 29.03 21 9946 9016 70909461
Acidosis 39.14 29.03 27 9940 18236 70900241
Malaise 38.85 29.03 7 9960 432925 70485552
Dyspnoea 38.76 29.03 31 9936 770029 70148448
Renal failure 38.28 29.03 83 9884 188987 70729490
Disseminated intravascular coagulation 37.89 29.03 34 9933 33564 70884913
Dry gangrene 33.96 29.03 10 9957 879 70917598
Acute respiratory failure 32.68 29.03 39 9928 53626 70864851
Ventricular tachycardia 31.81 29.03 32 9935 36391 70882086
Fear 31.59 29.03 25 9942 20786 70897691
Renal tubular necrosis 31.30 29.03 26 9941 23145 70895332
Intestinal ischaemia 31.07 29.03 20 9947 12044 70906433
Ischaemic hepatitis 30.70 29.03 13 9954 3316 70915161
Anhedonia 30.42 29.03 21 9946 14192 70904285
Coma scale abnormal 30.08 29.03 17 9950 8099 70910378
Hypernatraemia 30.04 29.03 20 9947 12741 70905736
Asthenia 29.09 29.03 14 9953 457652 70460825

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01BA01 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
POSTERIOR PITUITARY LOBE HORMONES
Vasopressin and analogues
FDA CS M0022562 Vasopressins
FDA PE N0000009908 Vasoconstriction
FDA PE N0000175360 Decreased Diuresis
MeSH PA D050034 Antidiuretic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D045283 Natriuretic Agents
MeSH PA D014662 Vasoconstrictor Agents
CHEBI has role CHEBI:35554 cardiovascular agent
CHEBI has role CHEBI:50248 hematologic agents
CHEBI has role CHEBI:52290 mitogens

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nocturnal enuresis indication 8009008
Hereditary factor VIII deficiency disease indication 28293008 DOID:12134
von Willebrand disorder indication 128105004 DOID:12531
Partial Central Diabetes Insipidus indication
Cardiac arrest off-label use 410429000 DOID:0060319
Uremic Bleeding Tendency off-label use
Chronic glomerulonephritis contraindication 20917003
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Uremia contraindication 44730006 DOID:4676
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Asthma contraindication 195967001 DOID:2841
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.65 acidic
pKa2 12.19 acidic
pKa3 12.56 acidic
pKa4 12.85 acidic
pKa5 13.19 acidic
pKa6 13.43 acidic
pKa7 13.76 acidic
pKa8 10.75 Basic
pKa9 6.4 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9375478 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9687526 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9744209 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9744239 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
200UNITS/10ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 Dec. 17, 2016 RX SOLUTION INTRAVENOUS 9937223 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/100ML (0.2UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 21, 2021 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9375478 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9687526 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9744209 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
20UNITS/ML (20UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 17, 2014 RX SOLUTION INTRAVENOUS 9744239 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
40UNITS/100ML (0.4UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 10010575 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925233 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9925234 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9962422 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9968649 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9974827 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
60UNITS/100ML (0.6UNITS/ML) VASOSTRICT PAR STERILE PRODUCTS N204485 April 15, 2020 RX SOLUTION INTRAVENOUS 9981006 Jan. 30, 2035 TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
20UNITS/ML (20UNITS/ML) VASOPRESSIN EAGLE PHARMS A211538 Dec. 15, 2021 RX SOLUTION INTRAVENOUS July 17, 2022 PATENT CHALLENGE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Vasopressin V1a receptor GPCR AGONIST Ki 9.59 CHEMBL CHEMBL
Vasopressin V1b receptor GPCR AGONIST Ki 9.31 CHEMBL CHEMBL
Vasopressin V2 receptor GPCR AGONIST Ki 8.92 CHEMBL CHEMBL
Oxytocin receptor GPCR Ki 8.78 CHEMBL
Vasopressin V2 receptor GPCR IC50 8.48 CHEMBL
Oxytocin receptor GPCR Ki 8.93 CHEMBL
Vasopressin V2 receptor GPCR Ki 9.35 CHEMBL
Vasopressin V2 receptor GPCR Kd 8.82 CHEMBL
Vasopressin V1a receptor GPCR Kd 9.19 CHEMBL
Vasopressin V1b receptor GPCR Ki 9.54 CHEMBL
Vasopressin V1 receptor GPCR Kd 9.19 CHEMBL

External reference:

IDSource
4018654 VUID
N0000179795 NUI
D00101 KEGG_DRUG
4018654 VANDF
C1705480 UMLSCUI
CHEBI:9937 CHEBI
CHEMBL373742 ChEMBL_ID
CHEMBL2108986 ChEMBL_ID
DB00067 DRUGBANK_ID
2168 IUPHAR_LIGAND_ID
C016671 MESH_SUPPLEMENTAL_RECORD_UI
Y4907O6MFD UNII
1098 RXNORM
3144 MMSL
5667 MMSL
d00398 MMSL
002122 NDDF
002123 NDDF
002126 NDDF
005438 NDDF
005439 NDDF
126192003 SNOMEDCT_US
421078009 SNOMEDCT_US
772208008 SNOMEDCT_US
77671006 SNOMEDCT_US
CHEMBL1201528 ChEMBL_ID
644077 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0517-1020 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0517-1020 INJECTION, SOLUTION 20 [USPU] INTRAVENOUS NDA 25 sections
Vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 0548-9701 INJECTION 20 [USPU] INTRAVENOUS ANDA 24 sections
VASOPRESSIN HUMAN PRESCRIPTION DRUG LABEL 1 42367-570 INJECTION 20 U PARENTERAL ANDA 24 sections
vasopressin HUMAN PRESCRIPTION DRUG LABEL 1 70121-1642 INJECTION 20 [USPU] INTRAVENOUS ANDA 20 sections